Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a novel treatment for androgenetic alopecia in Korean individuals effectively reduced the affected areas and provided satisfactory outcomes for both male and female participants.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

This study found that oral minoxidil 5 mg daily significantly improves hair growth in men with androgenetic alopecia, although common side effects include hypertrichosis and pedal edema.

Finasteride and minoxidil together safely and effectively increase hair growth and density for androgenetic alopecia.

This study found that a topical compounded formulation may improve hair density and general appearance in male patients with androgenetic alopecia after 6 months of use.

This study observed that administering low-dose oral minoxidil during the daytime led to significantly greater hair density improvements in androgenetic alopecia patients compared to nighttime dosing. This suggests that circadian variations in hair follicle biology could be important for optimizing treatment outcomes.

This review highlights that combination pharmacotherapy for androgenetic alopecia may offer enhanced hair growth efficacy and reduced side effects through distinct mechanisms, allowing for personalized treatment regimens that improve patient compliance and therapeutic outcomes.

This study found that microneedling, alone or combined with drugs, was effective in reducing hair loss severity and increasing hair density in male androgenetic alopecia patients, with the combination therapy showing more significant results for moderate to severe cases.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

In this study, researchers found that combining topical 5% minoxidil with intradermal triamcinolone microinjections significantly improved hair density in women with androgenetic alopecia compared to minoxidil alone. However, further research is necessary to confirm these findings in a larger population.

This study found that conventional treatments like oral dutasteride and topical/oral minoxidil are effective for male androgenetic alopecia, and it provides guidance on the relative efficacy of some alternative treatments, such as topical melatonin and rosemary oil, compared to these conventional therapies.

Combining PRP with topical minoxidil is most effective for hair growth in androgenetic alopecia.

This study found that both red and green LED therapies combined with a microneedling patch significantly improved hair density and diameter in androgenetic alopecia patients over 24 weeks, with no serious side effects and similar efficacy between the two light wavelengths.

This randomized controlled trial investigated the impact of a placebo on non-vellus hair count in individuals with androgenetic alopecia, a common form of hair loss affecting both men and women, but results were not reported.

This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.

This study found that a cholesterol-conjugated, cell-penetrating asiRNA targeting the androgen receptor effectively reduced hair loss and promoted hair growth in mouse models of androgenetic alopecia, suggesting potential as a novel treatment.

This study found that intradermal injection of a specially designed RNA molecule, cp-asiAR, successfully reduced androgen receptor levels and promoted hair growth in a mouse model of androgenetic alopecia, while also improving hair follicle characteristics in ex vivo human scalp tissues without significant toxicity.

In this study, several photobiomodulation devices showed statistically significant improvement in hair growth for patients with androgenetic alopecia, with varying efficacy between devices and genders.

In this study, the application of Dr. SKS Hair Booster Serum, containing micronutrients and multivitamins, significantly improved hair density and reduced hair fall in 1,000 patients with androgenetic alopecia over six months, with no major adverse events reported and 95% patient satisfaction.

In this study, combining photobiomodulation therapy and pulsed electromagnetic field therapy over 24 weeks significantly increased hair density in androgenetic alopecia patients compared to a sham device control, with minimal side effects reported.

This study systematically reviewed the literature on nonsurgical treatments for androgenetic alopecia, such as 5% minoxidil, platelet-rich plasma, and low-level laser therapy, but results on their relative effectiveness were not reported.

This meta-analysis reported that dutasteride was more effective than finasteride in increasing hair count and improving visual hair appearance in men with androgenetic alopecia over a 24-week period, while both drugs had similar rates of sexual dysfunction side effects.

This study found that low-level laser therapy increased hair density in men with androgenetic alopecia, with even greater improvements seen when combined with finasteride.

This study found that the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair count and reduced daily hair shedding in patients with androgenetic alopecia over 16 weeks, although other measures did not differ from placebo.

This study found that sub-dermal platelet-rich plasma injections were effective for treating androgenic alopecia among both male and female participants.